Antibody–drug conjugates improve outcomes for patients with inoperable or metastatic breast cancer
Promising results reported for datopotamab deruxtecan and trastuzumab deruxtecan in HER2-non-amplified breast cancer
Induction chemotherapy before CRT improves outcomes in locally advanced cervical cancer
Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease
Combination therapies with immunotherapy and ADCs prolong overall survival in urothelial carcinoma
Positive outcomes in advanced or metastatic disease reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate an alternative to first-line chemotherapy for the first time
New treatment paradigms may offer advances in pancreatic cancer treatments
Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed
Triplet therapy does not outperform doublet treatment first line in metastatic pancreatic cancer
Results from the JCOG1611-GENERATE trial fuel the debate around the preferred option in this setting
Advanced pancreatic cancer: is triple chemotherapy into question?
Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens
Adding amivantamab to chemotherapy prolongs PFS in untreated EGFR exon 20 insertion-mutated advanced NSCLC
The bispecific EGFR/MET-directed monoclonal antibody looks set to become the standard of care in this setting, but toxicity has to be managed carefully
New data support perioperative nivolumab for patients with resectable NSCLC
CheckMate 77T demonstrates significantly improved event-free survival with neoadjuvant nivolumab plus chemotherapy followed by adjuvant nivolumab compared with chemotherapy and adjuvant placebo
Are we over-treating patients with locally advanced rectal cancer?
Recently presented results suggest that a subset of patients with early stage rectal cancer could skip pre-operative radiotherapy, thus raising some questions about the standard of care
Cemiplimab survival improvements in NSCLC are durable
Extended analyses from two regulatory phase III trials show that the benefits of anti-PD-1-based therapy persist long term, even in patients with brain metastases